Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bright Minds Biosciences Inc (DRUG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: DRUG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 649.14% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 226.37M USD | Price to earnings Ratio - | 1Y Target Price 92.32 |
Price to earnings Ratio - | 1Y Target Price 92.32 | ||
Volume (30-day avg) 46719 | Beta 1.13 | 52 Weeks Range 0.93 - 79.02 | Updated Date 03/30/2025 |
52 Weeks Range 0.93 - 79.02 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date 2025-03-11 | When - | Estimate - | Actual 0.0053 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.86% | Return on Equity (TTM) -51.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 215358018 | Price to Sales(TTM) - |
Enterprise Value 215358018 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.07 | Shares Outstanding 6988990 | Shares Floating 631097 |
Shares Outstanding 6988990 | Shares Floating 631097 | ||
Percent Insiders 27.28 | Percent Institutions 44.28 |
Analyst Ratings
Rating - | Target Price 4.87 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bright Minds Biosciences Inc
Company Overview
History and Background
Bright Minds Biosciences Inc. is a biotechnology company focused on developing novel drugs for the treatment of neuropsychiatric disorders, epilepsy, and pain. Founded in 2019, they have focused on developing serotonergic therapeutics targeting specific receptors.
Core Business Areas
- Drug Development: Development of novel serotonergic therapeutics targeting specific receptors for neuropsychiatric disorders, epilepsy, and pain.
- Preclinical Research: Conducting preclinical studies to evaluate the safety and efficacy of their drug candidates.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of their drug candidates in human subjects.
Leadership and Structure
The company is led by a management team with experience in drug development and biotechnology. Details about the specific team members can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- BMB-101: A 5-HT2C selective agonist being developed for Dravet Syndrome and other epilepsy indications. No current market share or revenue is available as it's in clinical development. Competitors include existing anti-epileptic drugs.
- BMB-202: A novel compound being developed for pain management. No current market share or revenue is available as it's in preclinical development. Competitors include opioid and non-opioid pain medications.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive. The neuropsychiatric and pain markets are large and growing, but also crowded with established players.
Positioning
Bright Minds is positioned as a company developing novel, targeted therapies for neuropsychiatric disorders, epilepsy, and pain. Their competitive advantage lies in their specific receptor-targeting approach.
Total Addressable Market (TAM)
The TAM for neuropsychiatric disorders, epilepsy, and pain is estimated to be in the billions of dollars. Bright Minds' position within this TAM depends on the successful development and commercialization of their drug candidates.
Upturn SWOT Analysis
Strengths
- Novel, targeted drug development approach
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Early-stage drug development pipeline
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of drug pipeline into new indications
- Positive clinical trial results
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Changes in regulatory environment
Competitors and Market Share
Key Competitors
- LLY (Eli Lilly and Company)
- ABBV (AbbVie)
- JNJ (Johnson & Johnson)
Competitive Landscape
Bright Minds faces strong competition from established pharmaceutical companies with greater financial and R&D resources. Bright Minds' advantage lies in its novel approach and specific receptor targets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by milestones in the drug development pipeline and fundraising activities. There is no product revenue at the moment.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of their drug candidates. Analyst estimates should be consulted.
Recent Initiatives: Recent initiatives include advancing their lead drug candidates into clinical trials, securing patents for their technology, and forming partnerships with research institutions.
Summary
Bright Minds Biosciences is an early-stage biotechnology company focused on developing novel treatments for neuropsychiatric disorders. Its strength lies in its targeted drug development approach. Weaknesses include limited financial resources and the high risk associated with drug development. Positive clinical trial outcomes are crucial for its success, while competition from larger pharmaceutical companies remains a threat.
Similar Companies
- LLY
- ABBV
- JNJ
- PFE
Sources and Disclaimers
Data Sources:
- Bright Minds Biosciences Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence. The data provided is based on publicly available information and may be subject to change. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bright Minds Biosciences Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-03-22 | Co-Founder, CEO, President & Director Mr. Ian McDonald | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://brightmindsbio.com |
Full time employees - | Website https://brightmindsbio.com | ||
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.